Acute Ischemic StrokeNCT06984965
Role of EEG in Differentiation Between Ischemic and Hemorrhagic Stroke
An observational study of Acute Ischemic Stroke and Acute Haemorrhagic Stroke, run by Assiut University at 1 site in Egypt.
Trial summary
Searching electrical activity registered by EEG in acute ischemic and hemorrhagic stroke and comparing these parameters to the post-stroke recovery patterns to investigate the role of EEG as a differentiation tool and as a predictor of post-stroke recovery. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Acute Ischemic Stroke, Acute Haemorrhagic Stroke
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Dec 2025to Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI, or acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT, onset <72 hours before expected time of performing EEG.
Who may be able to join
- Age above 18 and below 80 years.
- Acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI.
- Acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT.
- Stroke onset <72 hours before expected time of performing EEG.
- First-ever ischemic stroke.
- Measurable deficit on the National Institute of Health Stroke Scale (NIHSS).
- Able to give and sign informed consent.
Who cannot join
- Transient Ischemic Attacks (TIAs).
- Greater than 72 hours past the initial insult.
- Patients with subarachnoid haemorrhage, traumatic haemorrhage (epidural/subdural bleeding), cerebral venous sinus thrombosis, indication for urgent neurosurgical intervention.
- History of other central nervous system diseases.
- Any signs unfit for MRI/EEG scan.
- Injury or active infection of electrode cap placement area.
Show all 17Show fewer
- Claustrophobia; recognition disorder.
- Known skull defect or head trauma.
- Previous neurological procedure (metallic implant, brain pace, cranial operation history).
- Significant physical impairment that would restrict the ability to use the portable EEG devices.
- Presence of malignancy or systemic rheumatic disease
- Non-stroke disease or lesion affecting the sensorimotor system.
- Alcohol or drug addiction.
- Presence of pump/shunt.
- Presence of Malignancy.
- Presence of severe cognitive impairment.
- History of epilepsy or taking medication due to epilepsy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Neurology Department, Faculty of Medicine, Assiut University
Asyut, Asyut Governorate, 71511
Gena ELassall, 01028914897
Gena ELassall
About this study
Official title: Electroencephalogram (EEG) in Differentiation Between Ischemic and Hemorrhagic Stroke and Its Role as a Predictor of Post-stroke Recovery
Searching electrical activity registered by EEG in acute ischemic and hemorrhagic stroke and comparing these parameters to the post-stroke recovery patterns to investigate the role of EEG as a differentiation tool and as a predictor of post-stroke recovery.
Read the detailed description
In this study, EEG will be performed on each patient included; within 72 hours of the onset of the stroke. The EEG device will be used within the intended use as described in the user manuals. The electrodes are put on the patient's head, and the EEG signal is recorded for several minutes; the amplifier is used to amplify the EEG signal and reduce artifacts. A complete EEG and data will be collected at baseline and on follow-up to observe the differences in EEG patterns to perform a qualitative assessment of the EEG results.
EEG patterns depend on the size and location of acute ischemic stroke, including generalized or focal slowing or both and epileptiform discharges. Abnormal neuronal activity is determined by comparing a part of the patient's brain not affected by stroke to a part of the patient's brain affected by stroke. Moreover, Abnormal blood flow is interpreted by comparing the abnormal EEG patterns in the areas of infarctions or hemorrhage to the normal brain tissue signals. The aim is to compare electric waveforms from an EEG device between patients with acute ischemic and acute hemorrhagic stroke (at baseline which is within 72 hours of the onset of acute ischemic and acute hemorrhagic stroke and through study completion, an average of 3 to 6 months).
- Conditions
- Acute Ischemic Stroke, Acute Haemorrhagic Stroke
- Keywords
- EEG, Acute Ischaemic Stroke, Acute Haemorrhagic Stroke, Stroke Recovery
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ischaemic Stroke Group | Patients with ischemic arteria cerebri media infarct confirmed by MRI. | |
| Haemorrhagic Stroke Group | Patients with spontaneous intraparenchymal bleeding confirmed by CT. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Participants With Focal Slowing in the Stroke-Affected Hemisphere
Presence of focal slowing (e.g., increased delta or theta activity) in the stroke-affected hemisphere versus the unaffected hemisphere. Patterns categorized as "ischemic" or "hemorrhagic."; this will be measured in percentage (%).
Measured: Baseline (within 72 hours of stroke onset)
Proportion of Participants With Interhemispheric Asymmetry in EEG Waveforms
Qualitative assessment of EEG asymmetry between affected and unaffected hemispheres at baseline. Frequency of each will be measured in percentage (%).
Measured: Baseline (within 72 hours of stroke onset)
Proportion of Participants With Absent or Diminished EEG Reactivity
Absence or reduction in EEG reactivity to external stimuli (e.g., auditory, tactile) in the affected hemisphere; this will be measures by precentage (%).
Measured: Baseline (within 72 hours of stroke onset)
Proportion of Participants With Epileptiform Activity on EEG
Presence of epileptiform discharges (e.g., spikes or sharp waves) on EEG in the stroke-affected hemisphere; thsi will be measured by precentage (%).
Measured: Baseline (within 72 hours of stroke onset)
Secondary outcomes (2)
Correlation Between Baseline EEG Findings and Functional Recovery
Association between initial qualitative EEG abnormalities (e.g., focal slowing, asymmetry) and functional outcomes measured by standardized scales (e.g., Modified Rankin Scale) at 6 months; measured by Correlation coefficient (r).
Measured: Phase I (Baseline EEG assessment) and Phase III (3 to 6 month follow-up functional evaluation)
Prediction of Post-Stroke Seizures Based on EEG Findings
Proportion of participants with specific EEG abnormalities (e.g., epileptiform activity) at baseline who develop post-stroke seizures within 3 to 6 months, measured by percentage (%).
Measured: Phase I (Baseline EEG assessment) and Phase III (3 to 6 month follow-up functional evaluation)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2025
- Study start1 Dec 2025
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gena ELassall, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06984965
- Sponsor's protocol ID
- 04-2024-200998
- Status last verified
- Nov 2026
- First submitted
- 28 Dec 2024
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Electroencephalogram (EEG) in Differentiation Between Ischemic and Hemorrhagic Stroke and Its Role as a Predictor of Post-stroke Recovery
- ClinicalTrials.gov ID
- NCT06984965
- Acronym / sponsor ID
- 04-2024-200998
- Conditions
- Acute Ischemic Stroke, Acute Haemorrhagic Stroke
- Keywords
- EEG, Acute Ischaemic Stroke, Acute Haemorrhagic Stroke, Stroke Recovery
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 22 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Searching electrical activity registered by EEG in acute ischemic and hemorrhagic stroke and comparing these parameters to the post-stroke recovery patterns to investigate the role of EEG as a differentiation tool and as a predictor of post-stroke recovery.
Detailed description
In this study, EEG will be performed on each patient included; within 72 hours of the onset of the stroke. The EEG device will be used within the intended use as described in the user manuals. The electrodes are put on the patient's head, and the EEG signal is recorded for several minutes; the amplifier is used to amplify the EEG signal and reduce artifacts. A complete EEG and data will be collected at baseline and on follow-up to observe the differences in EEG patterns to perform a qualitative assessment of the EEG results.
EEG patterns depend on the size and location of acute ischemic stroke, including generalized or focal slowing or both and epileptiform discharges. Abnormal neuronal activity is determined by comparing a part of the patient's brain not affected by stroke to a part of the patient's brain affected by stroke. Moreover, Abnormal blood flow is interpreted by comparing the abnormal EEG patterns in the areas of infarctions or hemorrhage to the normal brain tissue signals. The aim is to compare electric waveforms from an EEG device between patients with acute ischemic and acute hemorrhagic stroke (at baseline which is within 72 hours of the onset of acute ischemic and acute hemorrhagic stroke and through study completion, an average of 3 to 6 months).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ischaemic Stroke Group | – | –Patients with ischemic arteria cerebri media infarct confirmed by MRI. |
| Haemorrhagic Stroke Group | – | –Patients with spontaneous intraparenchymal bleeding confirmed by CT. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI, or acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT, onset <72 hours before expected time of performing EEG.
Key inclusion criteria (7 listed)
- Age above 18 and below 80 years.
- Acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI.
- Acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT.
- Stroke onset <72 hours before expected time of performing EEG.
- First-ever ischemic stroke.
Key exclusion criteria (17 listed)
- Transient Ischemic Attacks (TIAs).
- Greater than 72 hours past the initial insult.
- Patients with subarachnoid haemorrhage, traumatic haemorrhage (epidural/subdural bleeding), cerebral venous sinus thrombosis, indication for urgent neurosurgical intervention.
- History of other central nervous system diseases.
- Any signs unfit for MRI/EEG scan.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of Participants With Focal Slowing in the Stroke-Affected Hemisphere
Time frame: Baseline (within 72 hours of stroke onset)
Presence of focal slowing (e.g., increased delta or theta activity) in the stroke-affected hemisphere versus the unaffected hemisphere. Patterns categorized as "ischemic" or "hemorrhagic."; this will be measured in percentage (%).
Proportion of Participants With Interhemispheric Asymmetry in EEG Waveforms
Time frame: Baseline (within 72 hours of stroke onset)
Qualitative assessment of EEG asymmetry between affected and unaffected hemispheres at baseline. Frequency of each will be measured in percentage (%).
Proportion of Participants With Absent or Diminished EEG Reactivity
Time frame: Baseline (within 72 hours of stroke onset)
Absence or reduction in EEG reactivity to external stimuli (e.g., auditory, tactile) in the affected hemisphere; this will be measures by precentage (%).
Proportion of Participants With Epileptiform Activity on EEG
Time frame: Baseline (within 72 hours of stroke onset)
Presence of epileptiform discharges (e.g., spikes or sharp waves) on EEG in the stroke-affected hemisphere; thsi will be measured by precentage (%).
2 secondary outcomes
Correlation Between Baseline EEG Findings and Functional Recovery
Time frame: Phase I (Baseline EEG assessment) and Phase III (3 to 6 month follow-up functional evaluation)
Prediction of Post-Stroke Seizures Based on EEG Findings
Time frame: Phase I (Baseline EEG assessment) and Phase III (3 to 6 month follow-up functional evaluation)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Ischemic Stroke
RecruitingObservational study
Continuous Dual Aspiration Technique With Zoom System for Stroke
Ischemic Stroke, Acute Stroke
Not yet recruitingPhase 2/3
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Not yet recruitingPhase 2/3
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
Acute Ischemic Stroke AIS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Ischemic Stroke and Acute Haemorrhagic Stroke, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gena ELassall, Bachelor of medicine and gener (+201028914897, genaelassall312@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Participants With Focal Slowing in the Stroke-Affected Hemisphere (time frame: Baseline (within 72 hours of stroke onset)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026; AzTrials last refreshed its copy on 7 Nov 2026.